United States:
After Bench Trial, Judge Sleet Concludes That Hospira’s Proposed Product Does Not Infringe The Patent-In-Suit Asserted By Abbvie
27 October 2014
Fox Rothschild LLP
To print this article, all you need is to be registered or login on Mondaq.com.
By Memorandum Opinion entered by The Honorable Gregory M. Sleet in Abbvie Inc.
v. Hospira, Inc., C.A. No. 11-648- GMS (D.Del., October 24, 2014),
the Court, following a two day bench trial and after having
considered the entire record in the case and the applicable law,
concluded that (1) the asserted claims of the patent-in-suit, U.S.
Patent Number 6,136,799 ("the '799 patent") are not
invalid due to obviousness; and (2) Hospira's proposed product
does not infringe the '799 patent.
A copy of the Memorandum Opinion is attached.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
